Nevin Sağsöz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nevin Sağsöz has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aykan Yucel
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ
5 shared publications - Cemile Dayangan Sayan
Department of Obstetrics and Gynecology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
4 shared publications Volkan Noyan
3 shared publications- Zehra Sema Ozkan
Department of obstetrics and gynecology, Firat University school of medicine, Elazig, Turkey
3 shared publications - Funda Bulut Arıkan
Kirikkale University, Faculty of Medicine, Department of Physiology, Kirikkale, Turkey
2 shared publications - Mahmut İlkin Yeral
Akdeniz University, Faculty of Medicine
2 shared publications
Latest Publications
- 30 April 2026
- Published by MediHealth Academy in Journal of Controversies in Obstetrics & Gynecology and Pediatrics
- Vol. 4 (2) , 25-30
Impact of dienogest therapy on CA125 levels, hormonal profile, and systemic inflammatory indices in endometriosis
Aims: The present study aims to evaluate the impact of dienogest therapy on CA125 levels, hormonal profile, and systemic inflammatory indices in patients with endometriosis, a chronic inflammatory disorder in which inflammation constitutes a fundamental component of the pathophysiology. Methods: This retrospective, pre–post analytical study included 150 female with endometriosis who received dienogest. Demographic and laboratory data were obtained from electronic medical records. Systemic inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-monocyte ratio (NMR), plateletto-lymphocyte ratio (PLR), mean platelet volume (MPV), MPV-to-lymphocyte ratio (MPVLR), cancer antigen 125 (CA-125), Systemic Immune-inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and pan-immune-inflammation value (PIV) were evaluated before and after treatment. Statistical analyses were performed using appropriate parametric and nonparametric tests, and correlation analyses were conducted. Results: Following dienogest therapy, statistically significant reductions were observed in CA125 levels (p=0.010) and PLR (p=0.028), along with decreases in leukocyte, and PCT levels. FSH levels showed a significant increase (p=0.001), whereas LH, estradiol, progesterone, TSH, FT3, and FT4 levels remained unchanged (p>0.05 for all). Significant increases were also noted in hemoglobin, hematocrit, MCV, and MCH values after treatment (p<0.05). No statistically significant differences were detected in NLR, MLR, NMR, MPVLR, SII, SIRI, or PIV. Correlation analyses demonstrated a positive association between CA 125 and PLR, as well as inverse correlations between CA125 and hematocrit. Conclusion: Dienogest therapy was associated with a reduction in CA125 levels and specific inflammatory markers, alongside improvements in certain hematological parameters in patients with endometriosis. These findings suggest a potential antiinflammatory benefit, indicating that dienogest may be involved in the modulation of systemic inflammatory burden. Furthermore, the preservation of endocrine homeostasis may support its favorable safety profile as an effective therapeutic option in the management of endometriosis.
- 30 April 2026
- Published by MediHealth Academy in Journal of Controversies in Obstetrics & Gynecology and Pediatrics
- Vol. 4 (2) , 25-30
Impact of dienogest therapy on CA125 levels, hormonal profile, and systemic inflammatory indices in endometriosis
Aims: The present study aims to evaluate the impact of dienogest therapy on CA125 levels, hormonal profile, and systemic inflammatory indices in patients with endometriosis, a chronic inflammatory disorder in which inflammation constitutes a fundamental component of the pathophysiology. Methods: This retrospective, pre–post analytical study included 150 female with endometriosis who received dienogest. Demographic and laboratory data were obtained from electronic medical records. Systemic inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-monocyte ratio (NMR), plateletto-lymphocyte ratio (PLR), mean platelet volume (MPV), MPV-to-lymphocyte ratio (MPVLR), cancer antigen 125 (CA-125), Systemic Immune-inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and pan-immune-inflammation value (PIV) were evaluated before and after treatment. Statistical analyses were performed using appropriate parametric and nonparametric tests, and correlation analyses were conducted. Results: Following dienogest therapy, statistically significant reductions were observed in CA125 levels (p=0.010) and PLR (p=0.028), along with decreases in leukocyte, and PCT levels. FSH levels showed a significant increase (p=0.001), whereas LH, estradiol, progesterone, TSH, FT3, and FT4 levels remained unchanged (p>0.05 for all). Significant increases were also noted in hemoglobin, hematocrit, MCV, and MCH values after treatment (p<0.05). No statistically significant differences were detected in NLR, MLR, NMR, MPVLR, SII, SIRI, or PIV. Correlation analyses demonstrated a positive association between CA 125 and PLR, as well as inverse correlations between CA125 and hematocrit. Conclusion: Dienogest therapy was associated with a reduction in CA125 levels and specific inflammatory markers, alongside improvements in certain hematological parameters in patients with endometriosis. These findings suggest a potential antiinflammatory benefit, indicating that dienogest may be involved in the modulation of systemic inflammatory burden. Furthermore, the preservation of endocrine homeostasis may support its favorable safety profile as an effective therapeutic option in the management of endometriosis.
- Open Access
- 25 August 2025
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 27 (2) , 217-224
ENHANCING DIAGNOSTIC ACCURACY IN POLYCYSTIC OVARY SYNDROME USING NOVEL INFLAMMATORY INDICES
Objectives: Polycystic ovary syndrome (PCOS) is characterized by a complicated and incompletely understood pathophysiology. This study investigates the role of inflammation in its pathophysiology, compares the diagnostic performance of inflammatory indices, and assesses the clinical utility of novel biomarkers. Material and Methods: This retrospective study included 30 patients with PCOS and 32 healthy controls. Inflammatory indices including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), neutrophil to monocyte ratio (NMR), platelet to lymphocyte ratio (PLR), platelet large cell ratio (PLCR), mean platelet volume to lymphocyte ratio (MPVLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), multi-inflammatory index (MII), and monocyte to high density lipoprotein ratio (MHR) were calculated. Receiver operating characteristic (ROC) curve analysis evaluated their diagnostic performance. Biochemical, hormonal, hematological, and inflammatory parameters were measured using ELISA and an automated analyzer. Results: Inflammatory indices SII (p=0.006), SIRI (p=0.022), MII (p=0.013), and MHR (p=0.003) were significantly higher in patients, while PLCR was lower (p=0.024). Biochemical parameters CRP (p=0.027), insulin (p=0.021), and LDL (p=0.027) were elevated, HDL decreased (p=0.035). ROC analysis identified MHR as the most accurate biomarker (AUC=0.747, 100% specificity), followed by CRP (AUC=0.726) and MII (AUC=0.713). SII and SIRI showed moderate but relevant accuracy. All were statistically significant (p< 0.05). Conclusion: The present study highlights the potential of inflammation-based indices particularly MHR, MII, SII, SIRI, and CRP as valuable biomarkers in PCOS diagnosis. MHR showed the strongest diagnostic performance (100% specificity), while CRP and MII also demonstrated good accuracy. SIRI’s high sensitivity supports its role in early detection, and both SII and SIRI may serve as complementary markers. Overall, the results underscore the significance of inflammation in PCOS and support the clinical utility of these markers. PCOS influences hematological and biochemical parameters as well as inflammatory indices.
- 25 August 2025
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 27 (2) , 217-224
Open AccessENHANCING DIAGNOSTIC ACCURACY IN POLYCYSTIC OVARY SYNDROME USING NOVEL INFLAMMATORY INDICES
Objectives: Polycystic ovary syndrome (PCOS) is characterized by a complicated and incompletely understood pathophysiology. This study investigates the role of inflammation in its pathophysiology, compares the diagnostic performance of inflammatory indices, and assesses the clinical utility of novel biomarkers. Material and Methods: This retrospective study included 30 patients with PCOS and 32 healthy controls. Inflammatory indices including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), neutrophil to monocyte ratio (NMR), platelet to lymphocyte ratio (PLR), platelet large cell ratio (PLCR), mean platelet volume to lymphocyte ratio (MPVLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), multi-inflammatory index (MII), and monocyte to high density lipoprotein ratio (MHR) were calculated. Receiver operating characteristic (ROC) curve analysis evaluated their diagnostic performance. Biochemical, hormonal, hematological, and inflammatory parameters were measured using ELISA and an automated analyzer. Results: Inflammatory indices SII (p=0.006), SIRI (p=0.022), MII (p=0.013), and MHR (p=0.003) were significantly higher in patients, while PLCR was lower (p=0.024). Biochemical parameters CRP (p=0.027), insulin (p=0.021), and LDL (p=0.027) were elevated, HDL decreased (p=0.035). ROC analysis identified MHR as the most accurate biomarker (AUC=0.747, 100% specificity), followed by CRP (AUC=0.726) and MII (AUC=0.713). SII and SIRI showed moderate but relevant accuracy. All were statistically significant (p< 0.05). Conclusion: The present study highlights the potential of inflammation-based indices particularly MHR, MII, SII, SIRI, and CRP as valuable biomarkers in PCOS diagnosis. MHR showed the strongest diagnostic performance (100% specificity), while CRP and MII also demonstrated good accuracy. SIRI’s high sensitivity supports its role in early detection, and both SII and SIRI may serve as complementary markers. Overall, the results underscore the significance of inflammation in PCOS and support the clinical utility of these markers. PCOS influences hematological and biochemical parameters as well as inflammatory indices.
- Open Access
- 22 July 2025
- Published by Galenos Yayinevi in CAM and Sakura Medical Journal
- p. 9-16
Evaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome
Evaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome - Cam & Sakura Medical Journal
- 22 July 2025
- Published by Galenos Yayinevi in CAM and Sakura Medical Journal
- p. 9-16
Open AccessEvaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome
Evaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome - Cam & Sakura Medical Journal
- Open Access
- 22 October 2024
- Published by International Journal of Women's Health and Reproduction Sciences in International Journal of Women's Health and Reproduction Sciences
- Vol. 12 (4) , 150-151
HPV Vaccine as Adjuvant Therapy in HPV Lesions
P ersistent infection with HPV is responsible for nearly 70% of vulvar/vaginal cancers, 90% of cervical and anal cancers, 70% of oropharyngeal cancers, and 60% of penile cancers (1). It has been observed that the use of prophylactic HPV vaccines can lead to a significant reduction in these cancers (2). Eradication of the virus depends primarily on cell-mediated immunity, after which antigen-presenting cells present mainly E2 and E6 proteins of HPV to T helper cells, ending with the activation of cytotoxic T cells. To a lesser degree, humoral responses of the immune system to the L1 protein are also significant. However, in natural HPV infection, the antibody response is considerably weaker than in vaccinated individuals (3). U.S. Food and Drug Administration (FDA) licensed three types of HPV. After the year of 2016, the 9-valent form of HPV vaccine was administered as the primary one in the United States. After 2018, this vaccine was approved for use between the ages of 9-45 (1). The primary protection mechanism provided by HPV vaccines is through neutralizing antibodies formed against L1/HPV-like particles-the high amounts of neutralizing antibodies formed by the vaccine act before the virus enters the cell. Therefore, the vaccine is not therapeutic and is not expected to affect the virus in patient cells. In current practices, it is recommended that individuals be vaccinated before they become infected for the best protection. However, HPV screening is not recommended before vaccination (3,4). Nevertheless, if someone who has previously been exposed to HPV is vaccinated, the vaccine is likely to provide an advantage to the patient through the following mechanisms: • Prevention of reinfection/reactivation: Although the new infection rate decreases with age, reinfections can occur. Randomized controlled trials have shown that vaccination in women aged 24 to 45 prevents new HPV infections and disease (4,5). • Broder protection: While the vaccine targets specific HPV types, it may provide some cross-protection against other types, which could be beneficial for
- 22 October 2024
- Published by International Journal of Women's Health and Reproduction Sciences in International Journal of Women's Health and Reproduction Sciences
- Vol. 12 (4) , 150-151
Open AccessHPV Vaccine as Adjuvant Therapy in HPV Lesions
P ersistent infection with HPV is responsible for nearly 70% of vulvar/vaginal cancers, 90% of cervical and anal cancers, 70% of oropharyngeal cancers, and 60% of penile cancers (1). It has been observed that the use of prophylactic HPV vaccines can lead to a significant reduction in these cancers (2). Eradication of the virus depends primarily on cell-mediated immunity, after which antigen-presenting cells present mainly E2 and E6 proteins of HPV to T helper cells, ending with the activation of cytotoxic T cells. To a lesser degree, humoral responses of the immune system to the L1 protein are also significant. However, in natural HPV infection, the antibody response is considerably weaker than in vaccinated individuals (3). U.S. Food and Drug Administration (FDA) licensed three types of HPV. After the year of 2016, the 9-valent form of HPV vaccine was administered as the primary one in the United States. After 2018, this vaccine was approved for use between the ages of 9-45 (1). The primary protection mechanism provided by HPV vaccines is through neutralizing antibodies formed against L1/HPV-like particles-the high amounts of neutralizing antibodies formed by the vaccine act before the virus enters the cell. Therefore, the vaccine is not therapeutic and is not expected to affect the virus in patient cells. In current practices, it is recommended that individuals be vaccinated before they become infected for the best protection. However, HPV screening is not recommended before vaccination (3,4). Nevertheless, if someone who has previously been exposed to HPV is vaccinated, the vaccine is likely to provide an advantage to the patient through the following mechanisms: • Prevention of reinfection/reactivation: Although the new infection rate decreases with age, reinfections can occur. Randomized controlled trials have shown that vaccination in women aged 24 to 45 prevents new HPV infections and disease (4,5). • Broder protection: While the vaccine targets specific HPV types, it may provide some cross-protection against other types, which could be beneficial for
- 4 April 2024
- Published by Nobel Tip Kitabevleri
- p. 185-189
Screening Cytomegalovirus Infection during Pregnancy
CMV infection is widespread throughout the world and the risk of transmission between people through body secretions is high. During pregnancy, not only primary infections but also non-primary infections can be transmitted transplacental to the baby. It can cause serious mortality and morbidity in the fetus/newborn and is the most important cause of neurosensory hearing loss. There are new treatment motivations for this disease, for which there is no vaccine to date. Although current guidelines do not routinely recommend universal treatment, targeted therapy is important during pregnancy.
- 4 April 2024
- Published by Nobel Tip Kitabevleri
- p. 185-189
Screening Cytomegalovirus Infection during Pregnancy
CMV infection is widespread throughout the world and the risk of transmission between people through body secretions is high. During pregnancy, not only primary infections but also non-primary infections can be transmitted transplacental to the baby. It can cause serious mortality and morbidity in the fetus/newborn and is the most important cause of neurosensory hearing loss. There are new treatment motivations for this disease, for which there is no vaccine to date. Although current guidelines do not routinely recommend universal treatment, targeted therapy is important during pregnancy.
- 4 April 2024
- Published by Nobel Tip Kitabevleri
- p. 177-183
Screening of Fetal Aneuploidies Using Fetal Cell-Free DNA
Fetal aneuploidies have been attempted to be screened since the 1970s. For this purpose, maternal age, various serum biochemical tests on maternal serum, and fetal ultrasonography have been used and are being used. However, it is observed that all these tests are insufficient to detect aneuploidies. The best screening method today is the cf-DNA test, which is made from DNA particles of the fetus and placenta from the mother’s blood, and its detection rates are very high. The most important problem with this test today is cost.
- 4 April 2024
- Published by Nobel Tip Kitabevleri
- p. 177-183
Screening of Fetal Aneuploidies Using Fetal Cell-Free DNA
Fetal aneuploidies have been attempted to be screened since the 1970s. For this purpose, maternal age, various serum biochemical tests on maternal serum, and fetal ultrasonography have been used and are being used. However, it is observed that all these tests are insufficient to detect aneuploidies. The best screening method today is the cf-DNA test, which is made from DNA particles of the fetus and placenta from the mother’s blood, and its detection rates are very high. The most important problem with this test today is cost.
- Open Access
- 1 January 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (2) , 536-543
Could maternal serum MFG-E8 level predict adverse first trimester pregnancy outcome? A preliminary study
Background/aim: Milk fat globule-epidermal growth factor 8 (MFG-E8) is expressed in the endometrial epithelium and its expression increases during the implantation process. Due to this knowledge, we aimed to investigate the maternal serum MFG-E8 levels on both healthy pregnant women in the first trimester and pregnant women complicated with missed abortion and threatened abortion in the first trimester. Materials and methods: This prospective, cross-sectional study was conducted in a tertiary referral hospital, department of obstetrics between July 2020 and February 2021 after ethical committee approval. The study population was consisted of 30 healthy pregnant women (HP) in the first trimester, 30 pregnant women suffering from threatened abortion (TA) in the first trimester and 30 pregnant women suffering from missed abortion (MA) in the first trimester. Maternal serum MFG-E8 levels were analyzed with enzyme linked immunosorbent assay. Delivery and neonatal outcomes of the study population was evaluated. The continuous variables were compared among three groups with variance analysis with post hoc tests. The categorical variables were compared with chi-square and Fisher's exact tests where applicable. Results: The mean age of the study population was 29.36 ± 5.31 years. There was no significant difference among three groups for parameters of age, body mass index, parity number, and gestational week. Despite being within normal ranges, the mean neutrophil and international normalized ratio values of the three groups showed statistically significant difference (p < 0.05). The mean maternal serum MFG-E8 levels of MA, TA, and HP groups were 270 ± 152.3, 414.7 ± 236.7, and 474 ± 222.5 ng/mL, respectively (p = 0.001). It was found that mean of MFG-E8 of the MA group was statistically significantly lower than those of the other two groups (p < 0.05). Conclusion: Although maternal serum MFG-E8 level seems to be a parameter that differ between live and nonlive pregnancies, studies with large number of cases are needed to discuss our results and to determine a cut-off value for prediction
- 1 January 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (2) , 536-543
Open AccessCould maternal serum MFG-E8 level predict adverse first trimester pregnancy outcome? A preliminary study
Background/aim: Milk fat globule-epidermal growth factor 8 (MFG-E8) is expressed in the endometrial epithelium and its expression increases during the implantation process. Due to this knowledge, we aimed to investigate the maternal serum MFG-E8 levels on both healthy pregnant women in the first trimester and pregnant women complicated with missed abortion and threatened abortion in the first trimester. Materials and methods: This prospective, cross-sectional study was conducted in a tertiary referral hospital, department of obstetrics between July 2020 and February 2021 after ethical committee approval. The study population was consisted of 30 healthy pregnant women (HP) in the first trimester, 30 pregnant women suffering from threatened abortion (TA) in the first trimester and 30 pregnant women suffering from missed abortion (MA) in the first trimester. Maternal serum MFG-E8 levels were analyzed with enzyme linked immunosorbent assay. Delivery and neonatal outcomes of the study population was evaluated. The continuous variables were compared among three groups with variance analysis with post hoc tests. The categorical variables were compared with chi-square and Fisher's exact tests where applicable. Results: The mean age of the study population was 29.36 ± 5.31 years. There was no significant difference among three groups for parameters of age, body mass index, parity number, and gestational week. Despite being within normal ranges, the mean neutrophil and international normalized ratio values of the three groups showed statistically significant difference (p < 0.05). The mean maternal serum MFG-E8 levels of MA, TA, and HP groups were 270 ± 152.3, 414.7 ± 236.7, and 474 ± 222.5 ng/mL, respectively (p = 0.001). It was found that mean of MFG-E8 of the MA group was statistically significantly lower than those of the other two groups (p < 0.05). Conclusion: Although maternal serum MFG-E8 level seems to be a parameter that differ between live and nonlive pregnancies, studies with large number of cases are needed to discuss our results and to determine a cut-off value for prediction
- Open Access
- 2 December 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (12) , 1093-1096
Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model
Objective: Ovarian hyperstimulation syndrome is an iatrogenic condition that occurs in the treatment of infertility. There is no specific treatment available for OHSS. Cabergoline is a dopamine receptor 2 agonist and VEGF-VEGF2 receptor antagonist . Recently, cabergoline has been widely used to prevent the development of OHSS and reduce its severity Serotonin is known as a neurotransmitter and thought to have a role in the mechanism of angiogenesis and in signaling in endothelial cells. Serotonin is said to have similar effects to VEGF . Ondansetron is Selective Serotonin (5-HT3) Receptor Antagonist . It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. In the clinical practice today, there is no choice other than cabergoline, to prevent occurrence and reduce severity of OHSS, and sometimes its effects are limited. Methods: In our study, we compared the effect of cabergoline and ondansetron. 32 immature rats were used and the OHSS model was created. Parameters such as hematocrit value , ovarian size, the number of follicles in the ovary, endometrial capillary congestion and thickness values were evaluated and compared. Results: As a result, in our study, it was seen that ondansetron was effective on OHSS in many parameters. It is thought to be as effective as cabergoline. When we look at the literature, this is the first study in which ondansetron was evaluated for this purpose. It would be good to show this effect of ondansetron with other studies.
- 2 December 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (12) , 1093-1096
Open AccessEffect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model
Objective: Ovarian hyperstimulation syndrome is an iatrogenic condition that occurs in the treatment of infertility. There is no specific treatment available for OHSS. Cabergoline is a dopamine receptor 2 agonist and VEGF-VEGF2 receptor antagonist . Recently, cabergoline has been widely used to prevent the development of OHSS and reduce its severity Serotonin is known as a neurotransmitter and thought to have a role in the mechanism of angiogenesis and in signaling in endothelial cells. Serotonin is said to have similar effects to VEGF . Ondansetron is Selective Serotonin (5-HT3) Receptor Antagonist . It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. In the clinical practice today, there is no choice other than cabergoline, to prevent occurrence and reduce severity of OHSS, and sometimes its effects are limited. Methods: In our study, we compared the effect of cabergoline and ondansetron. 32 immature rats were used and the OHSS model was created. Parameters such as hematocrit value , ovarian size, the number of follicles in the ovary, endometrial capillary congestion and thickness values were evaluated and compared. Results: As a result, in our study, it was seen that ondansetron was effective on OHSS in many parameters. It is thought to be as effective as cabergoline. When we look at the literature, this is the first study in which ondansetron was evaluated for this purpose. It would be good to show this effect of ondansetron with other studies.
- 17 January 2022
- Published by International Journal of Women's Health and Reproduction Sciences in International Journal of Women's Health and Reproduction Sciences
- Vol. 10 (1) , 1-2
Does COVID-19 Infection Affect Female Reproductive System?
- 17 January 2022
- Published by International Journal of Women's Health and Reproduction Sciences in International Journal of Women's Health and Reproduction Sciences
- Vol. 10 (1) , 1-2
Does COVID-19 Infection Affect Female Reproductive System?
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 305-307
Attention-Deficit Hyperactivity disorder in adult primary dysmenorrhea patients
The aim of this study is to evaluate attention-deficit hyperactivity disorder in adult primary dysmenorrhea patients. 62 primary dysmenorrhea patients and 52 control group members are included in the study. Demographic characteristics such as education level and age were noted. Attention-deficit hyperactivity disorder symptoms were identified by the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale, Short Form-36 and also Hospital Anxiety and Depression Scale were conducted. According to the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale scores primary dysmenorrhea patients had a significantly higher rate compared to the control group. In bivariate analysis, Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale scores were found to have an association with Short Form-36 physical and mental component scores, anxiety and depression scores. Symptoms of attention-deficit hyperactivity disorder may be confronted in primary dysmenorrhea patients.
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 305-307
Attention-Deficit Hyperactivity disorder in adult primary dysmenorrhea patients
The aim of this study is to evaluate attention-deficit hyperactivity disorder in adult primary dysmenorrhea patients. 62 primary dysmenorrhea patients and 52 control group members are included in the study. Demographic characteristics such as education level and age were noted. Attention-deficit hyperactivity disorder symptoms were identified by the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale, Short Form-36 and also Hospital Anxiety and Depression Scale were conducted. According to the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale scores primary dysmenorrhea patients had a significantly higher rate compared to the control group. In bivariate analysis, Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale scores were found to have an association with Short Form-36 physical and mental component scores, anxiety and depression scores. Symptoms of attention-deficit hyperactivity disorder may be confronted in primary dysmenorrhea patients.